Evolution Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Evolution Wealth Management's VRTX Position: Q2 2026 in Review
Evolution Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, buying an estimated $11.5K and bringing the position to 78 shares worth $38.7K. The position accounts for 0.02% of the portfolio, ranked #347.
Evolution Wealth Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Evolution Wealth Management held 78 shares of Vertex Pharmaceuticals worth $38.7K as of Q2 2026.
- Evolution Wealth Management bought 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
- Vertex Pharmaceuticals made up 0.02% of Evolution Wealth Management's portfolio in Q2 2026, its #347 holding.
- Evolution Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Evolution Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.